Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Surgery
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Surgery
    Bariatric Surgery May Resolve Complications of Liver Disease - (DGNews)
    Multidetector CT Cystography Accurately Detects Urine Leaks After Prostatectomy - (DGNews)
    Study Shows Carotid Surgery Outcome No Different With Local, General Anaesthesia - (DGNews)
    Receipt of Heart Assist Pumps by Medicare Patients Associated With Poor Outcomes, High Costs - (DGNews)
    Type of Breast Reconstruction Impacts Radiation Therapy Outcomes - (DGNews)

    News archive

     Recent webcasts/CME - Surgery
      Adult Congenital Heart Disease Symposium
      Orthopedic Surgery 2007 Update
      Venous Thromboembolism Prophylaxis in the Surgical Cancer Patient
      Update on Aortic Surgery: Current Options for Aortic Repair
      Treatment Options for Advanced CHF: Neurohormonal Suppression to Surgery

      Webcasts/CME archive

       Recent cases - Surgery
        Experience with Adjuvant Chemotherapy for Pseudomyxoma Peritonei Secondary to Mucinous Adenocarcinoma of the Appendix with Oxaliplatin / Fluorouracil /Leucovorin (FOLFOX4)
        Transsacral Colon Fistula : Late Complication after Resection, Irradiation and Free Flap Transfer of Sacral Chondrosarcoma
        Metastatic Colorectal Cancer to a Primary Thyroid Cancer
        Severe Adult Ileosigmoid Intussusception Prolapsing from the Rectum: A Case Report
        A Resected Case of Solitary Pancreatic Metastasis from Adenocarcinoma of the Lung

        Cases archive
          




        my personal edition > surgery > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Methylnaltrexone Speeds Recovery of Bowel Function After Intestinal Surgery: Presented at SSO

        By John Gever

        WASHINGTON, DC -- March 20, 2007 -- Methylnaltrexone, a selective opioid antagonist drug, appears to accelerate recovery of intestinal motility after bowel resection, according to phase 2 data presented here at the 60th annual meeting of the Society of Surgical Oncology (SSO).

        Surgical treatment of colorectal cancer is typically followed by several days of ileus, which may be exacerbated and prolonged by opioid medications such as morphine. It has been proposed that opioid receptor antagonists may counteract this effect of opioid drugs, allowing faster recovery of normal bowel function and potentially shortening hospital stays.

        There is currently no approved treatment for postoperative ileus.

        In an oral presentation on March 16th, Eugene Viscusi, MD, director, acute pain management service, Jefferson Medical College, Philadelphia, Pennsylvania, United States, reported results from a double-blind, randomised, placebo-controlled trial of methylnaltrexone. The agent is selective for peripheral opioid receptors, so that it should not affect the central analgesic effects of opioid drugs.

        The trial enrolled 66 patients who had undergone segmental laparoscopic colectomy and were randomised to placebo or methylnaltrexone at 0.30 mg/kg by 20-minute infusion every 6 hours for a maximum of 7 days. Treatment was ended earlier if the patient had tolerated solid food for 24 hours or was discharged from the hospital.

        Mean time to first bowel movement after surgery occurred 20 hours faster with methylnaltrexone, Dr. Viscusi reported (98.0 vs. 118.1 hours, P = .038).

        Discharge eligibility was achieved more than a full day sooner with the active drug (116.1 vs. 148.7 hours, P = .049).

        Nonsignificant trends favouring methylnaltrexone were seen with other parameters, such as actual time to discharge and toleration of solid foods.

        Dr. Viscusi said it was also notable that many more adverse events were seen in the placebo group, especially nausea and vomiting.

        Methylnaltrexone was well tolerated, and hypotension was the only event reported more frequently compared with placebo.

        Opioid doses and pain scores were similar in the 2 groups, which suggests that methylnaltrexone did not impair the efficacy of analgesis treatment.

        Two phase 3 trials of methylnaltrexone are now underway, Dr. Viscusi said. The drug is under development by Progenics Pharmaceuticals.


        [Presentation title: Methylnaltrexone Bromide Administered Postoperatively to Patients Following Segmental Colectomy May Accelerate GI Recovery and Hospital Discharge Without Affecting Opioid Analgesia. Abstract 15]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send